These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 28881380)
1. Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. Hoskins PJ; Gotlieb WH CA Cancer J Clin; 2017 Nov; 67(6):493-506. PubMed ID: 28881380 [TBL] [Abstract][Full Text] [Related]
2. Inadequate Rates of BRCA Testing with its Negative Consequences for Women with Epithelial Ovarian Cancer and their Families: an Overview of the Literature. Hoskins PJ Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):472-483. PubMed ID: 29735311 [TBL] [Abstract][Full Text] [Related]
3. Uptake of testing for germline Stearnes G; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Cohen PA Int J Gynecol Cancer; 2019 Jul; 29(6):1038-1042. PubMed ID: 31101686 [TBL] [Abstract][Full Text] [Related]
4. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. George A; Kaye S; Banerjee S Nat Rev Clin Oncol; 2017 May; 14(5):284-296. PubMed ID: 27958297 [TBL] [Abstract][Full Text] [Related]
5. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Moyer VA; Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376 [TBL] [Abstract][Full Text] [Related]
6. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB JAMA; 2019 Aug; 322(7):652-665. PubMed ID: 31429903 [TBL] [Abstract][Full Text] [Related]
7. BRACAnalysis CDx as a companion diagnostic tool for Lynparza. Gunderson CC; Moore KN Expert Rev Mol Diagn; 2015; 15(9):1111-6. PubMed ID: 26292709 [TBL] [Abstract][Full Text] [Related]
8. Genetic testing in ovarian cancer - clinical impact and current practices. Knabben L; Imboden S; Mueller MD Horm Mol Biol Clin Investig; 2019 Oct; 41(3):. PubMed ID: 31577534 [TBL] [Abstract][Full Text] [Related]
9. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
10. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442 [TBL] [Abstract][Full Text] [Related]
11. A universal genetic testing initiative for patients with high-grade, non-mucinous epithelial ovarian cancer and the implications for cancer treatment. Bednar EM; Oakley HD; Sun CC; Burke CC; Munsell MF; Westin SN; Lu KH Gynecol Oncol; 2017 Aug; 146(2):399-404. PubMed ID: 28610746 [TBL] [Abstract][Full Text] [Related]
12. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Vergote I; Banerjee S; Gerdes AM; van Asperen C; Marth C; Vaz F; Ray-Coquard I; Stoppa-Lyonnet D; Gonzalez-Martin A; Sehouli J; Colombo N Eur J Cancer; 2016 Dec; 69():127-134. PubMed ID: 27821315 [TBL] [Abstract][Full Text] [Related]
14. Impact of Clinical Genetics Attendance at a Gynecologic Oncology Tumor Board on Referrals for Genetic Counseling and BRCA Mutation Testing. Cohen PA; Nichols CB; Schofield L; Van Der Werf S; Pachter N Int J Gynecol Cancer; 2016 Jun; 26(5):892-7. PubMed ID: 27051053 [TBL] [Abstract][Full Text] [Related]
15. Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer. Trainer AH; Meiser B; Watts K; Mitchell G; Tucker K; Friedlander M Int J Gynecol Cancer; 2010 Jul; 20(5):704-16. PubMed ID: 20973257 [TBL] [Abstract][Full Text] [Related]
16. Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions. Lheureux S; Karakasis K; Harter P; Scott C; Bacon M; Bryce J; Le Fur N; Pujade-Lauraine E; Oza AM Gynecol Oncol; 2016 Jan; 140(1):90-4. PubMed ID: 26475959 [TBL] [Abstract][Full Text] [Related]
17. Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. Tomao F; Bardhi E; Di Pinto A; Sassu CM; Biagioli E; Petrella MC; Palaia I; Muzii L; Colombo N; Panici PB Cancer Treat Rev; 2019 Nov; 80():101909. PubMed ID: 31629204 [TBL] [Abstract][Full Text] [Related]
18. PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. Gadducci A; Guerrieri ME Anticancer Res; 2016 May; 36(5):2055-64. PubMed ID: 27127105 [TBL] [Abstract][Full Text] [Related]
19. Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. Weren RD; Mensenkamp AR; Simons M; Eijkelenboom A; Sie AS; Ouchene H; van Asseldonk M; Gomez-Garcia EB; Blok MJ; de Hullu JA; Nelen MR; Hoischen A; Bulten J; Tops BB; Hoogerbrugge N; Ligtenberg MJ Hum Mutat; 2017 Feb; 38(2):226-235. PubMed ID: 27767231 [TBL] [Abstract][Full Text] [Related]
20. The integration of BRCA testing into oncology clinics. Percival N; George A; Gyertson J; Hamill M; Fernandes A; Davies E; Rahman N; Banerjee S Br J Nurs; 2016 Jun; 25(12):690-4. PubMed ID: 27345073 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]